Potentialiser la perte de poids avec les agonistes des récepteurs du GLP-1.

Scheen, André; Paquot, Nicolas

Request a copy

Article (Scientific journals)

Potentialiser la perte de poids avec les agonistes des récepteurs du GLP-1.

Scheen, André; Paquot, Nicolas

2021 • In Revue Médicale Suisse, 17 (747), p. 1405-1410

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/264349

PubMed
34431633

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

RMS SCHEEN PAQUOT perte de poids.pdf

Publisher postprint (211.16 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Diabetes Mellitus, Type 2/drug therapy; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Pharmaceutical Preparations; Weight Loss

Abstract :

[en] Glucagon-like peptide-1 receptor agonists are the antidiabetic agents that are associated with the greatest weight loss beyond a marked reduction in glycated haemoglobin. Weight loss results from a reduction in appetite through a predominant central effect combined with a peripheral effect. Liraglutide and semaglutide are developed for the treatment of obesity, independently of type 2 diabetes. Three approaches may be considered to potentiate weight loss: an increase of the drug dosage because of the demonstration of a dose-response, an add-on therapy with a sodium-glucose cotransporter type 2 inhibitor as this agent exerts a complementary action through urinary calorie loss (glucosuria) or a combination of the effects of two incretin hormones (GLP-1 and GIP), as the potent dual agonist tirzepatide currently in development.

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Paquot, Nicolas ; Université de Liège - ULiège > Département des sciences de la santé publique > Diabétologie, nutrition et maladies métaboliques

Language :

French

Title :

Potentialiser la perte de poids avec les agonistes des récepteurs du GLP-1.

Alternative titles :

[en] Potentiation of weight reduction with GLP-1 receptor agonists

Publication date :

2021

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Volume :

Issue :

747

Pages :

1405-1410

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 18 October 2021

Statistics

Number of views

147 (1 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Scheen AJ, Paquot N. Traitement des patients diabétiques de type 2 à risque cardio-rénal : ADA-EASD versus ESC. Rev Med Suisse 2020; 16:1478-82.
Scheen AJ. Cardiovascular Outcome Studies in Type 2 Diabetes: Comparison between SGLT2 Inhibitors and GLP-1 Receptor Agonists. Diabetes Res Clin Pract 2018; 143:88-100.
Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, Mortality, and Kidney Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials. Lancet Diabetes Endocrinol 2019; 7:776-85.
Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss: Systematic Review and Meta-analyses of Randomised Controlled Trials. BMJ 2012; 344:d7771.
Van Gaal L, Scheen A. Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment. Diabetes Care 2015; 38:1161-72.
Meier JJ. GLP-1 Receptor Agonists for Individualized Treatment of Type 2 Diabetes Mellitus. Nat Rev Endocrinol 2012; 8:728-42.
Scheen AJ. GLP-1 Receptor Agonists and Cardiovascular Protection. Class Effect or Not? Diabetes Metab 2018; 44:193-6.
Mantsiou C, Karagiannis T, Kakotrichi P, et al. Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors as Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Diabetes Obes Metab 2020; 22:1857-68.
Scheen AJ. Combinaison « inhibiteur des SGLT2-agoniste des récepteurs du GLP-1 » pour traiter le diabète de type 2. Rev Med Suisse 2019; 15:1436-41.
Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther 2021; 12:143-57.
Bray GA, Ryan DH. Evidence-Based Weight Loss Interventions: Individualized Treatment Options to Maximize Patient Outcomes. Diabetes Obes Metab 2021; 23(Suppl.1):50-62.
Brierley DI, Holt MK, Singh A, et al. Central and Peripheral GLP-1 Systems Independently Suppress Eating. Nat Metab 2021; 3:258-73.
Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide Lowers Body Weight in Rodents Via Distributed Neural Pathways. JCI Insight 2020; 5:e133429.
Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373:11-22.
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384:989.
Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss among Patients with Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA 2015; 314:687-99.
Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3 Trial. Lancet 2021; 397:971-84.
Wing RR, Marcus MD, Epstein LH, Salata R. Type II Diabetic Subjects Lose Less Weight than Their Overweight Nondiabetic Spouses. Diabetes Care 1987; 10:563-6.
Scheen AJ. Le liraglutide à la dose de 3 mg (Saxenda®) : Indication dans le traitement de l obésité. Rev Med Liege 2016; 71:256-61.
Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide Vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 2021; 325:1414-25.
Blundell J, Finlayson G, Axelsen M, et al. Effects of Once-Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects with Obesity. Diabetes Obes Metab 2017; 19:1242-51.
Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The Effect of Semaglutide 2.4 mg Once Weekly on Energy Intake, Appetite, Control of Eating, and Gastric Emptying in Adults with Obesity. Diabetes Obes Metab 2021; 23:754-62.
Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) Rationale and Design. Am Heart J 2020; 229:61-9.
Pereira MJ, Eriksson JW. Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs 2019; 79:219-30.
Ferrannini G, Hach T, Crowe S, et al. Energy Balance after Sodium Glucose Cotransporter 2 (SGLT2) Inhibition. Diabetes Care 2015; 38:1730-5.
Ludvik B, Frías JP, Tinahones FJ, et al. Dulaglutide as Add-on Therapy to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (AWARD-10): A 24-Week, Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Diabetes Endocrinol 2018; 6:370-81.
Blonde L, Belousova L, Fainberg U, et al. Liraglutide as Add-on to Sodium-Glucose Co-transporter-2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes: LIRA-ADD2SGLT2i, a 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Obes Metab 2020; 22:929-37.
Zinman B, Bhosekar V, Busch R, et al. Semaglutide Once Weekly as Add-on to SGLT-2 Inhibitor Therapy in Type 2 Diabetes (SUSTAIN 9): A Randomised, Placebo-Controlled Trial. Lancet Diabetes Endocrinol 2019; 7:356-67.
Saroka RM, Kane MP, Busch RS, Watsky J, Hamilton RA. SGLT-2 Inhibitor Therapy Added to GLP-1 Agonist Therapy in the Management of T2DM. Endocr Pract 2015; 21:1315-22.
Harashima SI, Inagaki N, Kondo K, et al. Efficacy and Safety of Canagliflozin as Add-on Therapy to a Glucagon-like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes Mellitus: A 52-Week, Open-Label, Phase IV Study. Diabetes Obes Metab 2018; 20:1770-5.
Seino Y, Yabe D, Sasaki T, et al. Sodium-Glucose Cotransporter-2 Inhibitor Luseogliflozin Added to Glucagon-like Peptide 1 Receptor Agonist Liraglutide Improves Glycemic Control with Bodyweight and Fat Mass Reductions in Japanese Patients with Type 2 Diabetes: A 52-Week, Open-Label, Single-Arm Study. J Diabetes Investig 2018; 9:332-40.
Deol H, Lekkakou L, Viswanath AK, Pappachan JM. Combination Therapy with GLP-1 Analogues and SGLT-2 Inhibitors in the Management of Diabesity: The Real World Experience. Endocrine 2017; 55:173-8.
Frías JP, Guja C, Hardy E, et al. Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy (DURATION-8): A 28 Week, Multicentre, Double-Blind, Phase 3, Randomised Controlled Trial. Lancet Diabetes Endocrinol 2016; 4:1004-16.
Jabbour SA, Frías JP, Hardy E, et al. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. Diabetes Care 2018; 41:2136-46.
Jabbour SA, Frías JP, Ahmed A, et al. Efficacy and Safety over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial. Diabetes Care 2020; 43:2528-36.
Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ. Weight Loss Variability with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus and Obesity: Mechanistic Possibilities. Obes Rev 2019; 20:816-28.
Goncalves E, Bell DSH. Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk. Diabetes Ther 2018; 9:919-26.
Goldenberg RM, Ahooja V, Clemens KK, et al. Practical Considerations and Rationale for Glucagon-like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes. Can J Diabetes 2021; 45:291-302.
Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab 2020; 31:410-21.
Hols JJ, Rosenkilde MM. GIP as a Therapeutic Target in Diabetes and Obesity: Insight from Incretin Co-agonists. J Clin Endocrinol Metab 2020; 105:e2710-e2716.
Willard FS, Douros JD, Gabe MB, et al. Tirzepatide Is an Imbalanced and Biased Dual GIP and GLP-1 Receptor Agonist. JCI Insight 2020; 5:e140532.
Frias JP, Nauck MA, Van J, et al. Efficacy and Safety of LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes: A Randomised, Placebo-Controlled and Active Comparator-Controlled Phase 2 Trial. Lancet 2018; 392:2180-93.
Lilly E. News Release: Tirzepatide Achieved Superior A1C and Body Weight Reductions Across all Three Doses Compared to Injectable Semaglutide in Adults with Type 2 Diabetes. 2021. Disponible sur : https://investor.lilly.com/news-releases/news-release-details/tirzepatide-achieved-superior-a1c-andbody-weight-reductions.